Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound technique could set the standard for healthy liver measurements

NCT ID NCT07714941

Knowledge-focused Sponsor: Asian Institute of Gastroenterology, India Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This observational study aims to determine what healthy liver tissue looks like on two new types of endoscopic ultrasound (EUS) measurements: attenuation imaging (ATI) and shear wave elastography (SWE). Researchers will enroll 100 adults who already need a diagnostic EUS for non-liver reasons and who have normal results on a standard FibroScan liver test. During the EUS, they will take additional ATI and SWE readings from the liver to establish preliminary normal reference values, which could help doctors better identify liver disease in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide doctors with normal ranges for two new ultrasound-based liver measurements, potentially improving early detection of fatty liver disease and liver stiffness.
What could go wrong
This is a small, early feasibility study with only 100 participants, so the reference values may not apply to everyone. The measurements are also operator-dependent and may vary between centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 years or older undergoing clinically indicated diagnostic endoscopic ultrasound (EUS) for non-hepatobiliary indications at AIG Hospitals will be screened for eligibility. Participants with normal FibroScan findings, defined as a Controlled Attenuation Parameter (CAP) \<238 dB/m and Liver Stiffness Measurement (LSM) \<7.5 kPa, who meet all eligibility criteria and provide written informed consent will be enrolled in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Undergoing clinically indicated diagnostic endoscopic ultrasound (EUS). * Same-day FibroScan examination available. * Controlled Attenuation Parameter (CAP) \<238 dB/m. * Liver Stiffness Measurement (LSM) \<7.5 kPa. * At least 10 valid FibroScan measurements. * FibroScan interquartile range (IQR)/median ≤30%. * Able and willing to provide written informed consent. Exclusion Criteria: * Known chronic liver disease. * Hepatitis B or Hepatitis C infection. * Significant alcohol consumption. * Decompensated cirrhosis. * Portal vein thrombosis. * Ascites. * Focal liver lesion. * Previous liver surgery. * Pregnancy. * Inadequate FibroScan examination. * Poor-quality EUS-guided Attenuation Imaging (ATI) or Shear Wave Elastography (SWE) acquisition. * Incomplete study data or withdrawal of informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-hepatobiliary indications are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-hepatobiliary indications

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AIG Hospitals

    Hyderabad, Telangana, 500032, India